Sagimet Biosciences Announces Leadership Changes
Retrieved on:
Thursday, July 20, 2023
Dick Rozek, Intellectual property, Partnership, University, Justice, Therapy, General counsel, NASH, Doctor of Philosophy, United States Department of Justice, Tobacco industry, Acne, MBA, RICO, San Diego, Organization, Santa Clara University, SAN, Corporation, Berkeley, FASN, CFO, Growth, Santa Barbara, Management, DRS
SAN MATEO, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today announced a series of leadership changes and appointments, designed to ensure a seamless transition into the next stage of growth for the company.
Key Points:
- SAN MATEO, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today announced a series of leadership changes and appointments, designed to ensure a seamless transition into the next stage of growth for the company.
- “It is my privilege to welcome Liz and Tony to the Sagimet leadership team.
- Ringold and Young for their decade of leadership and support as board members.”
Tony Rimac joined Sagimet earlier this year as Chief Operating Officer and will serve as Chief Financial Officer beginning in August. - He is a seasoned executive with a career spanning three decades of operating and financial leadership, the majority of which was dedicated to the life sciences industry.